KPV: The 3-Amino Acid Anti-Inflammatory That Works Orally
Last updated: March 2026
A tripeptide so small it survives digestion. Derived from alpha-MSH, KPV packs potent anti-inflammatory and antimicrobial activity into just three amino acids — with demonstrated oral bioavailability. Here's the research.
Oral or SubQ
Therapeutic Peptide
for Any Peptide
📋 On this page
What Is KPV?
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), positions 11-13. Despite being just three amino acids, it retains the full anti-inflammatory signaling of its 13-amino-acid parent hormone — without the melanogenic (skin-darkening) side effects. Its tiny size is the key to its unique oral bioavailability.
KPV's primary mechanism: it enters cells and directly inhibits NF-κB — the master transcription factor that drives inflammatory gene expression. By blocking NF-κB nuclear translocation, KPV suppresses production of TNF-α, IL-6, IL-1β, and other pro-inflammatory cytokines at the source. This is the same pathway targeted by many pharmaceutical anti-inflammatories, but through a different entry point. (Kannengiesser et al., J Biol Chem 2011)
Beyond anti-inflammatory effects, KPV demonstrates direct antimicrobial properties against Staphylococcus aureus and Candida albicans. The peptide disrupts microbial membranes and modulates innate immune responses. This dual anti-inflammatory + antimicrobial profile makes it particularly interesting for conditions involving both infection and inflammation, such as infected wounds and gut dysbiosis.
In IBD animal models, KPV reduces colonic inflammation, preserves epithelial barrier integrity, and promotes mucosal healing. The peptide crosses the intestinal barrier intact — thanks to its tiny size (just 3 residues) — allowing oral administration to deliver local gut effects. This is extremely rare for peptides, which are usually degraded by gastric enzymes. (Dalmasso et al., J Clin Invest 2008)
α-MSH activates melanocortin receptors (MC1R-MC5R), causing skin darkening and other hormonal effects. KPV retains the anti-inflammatory signaling but does NOT activate MC1R-dependent melanogenesis. This means anti-inflammatory benefits without the tanning, hormonal modulation, or other melanocortin side effects of full-length alpha-MSH or analogs like melanotan.
What the Research Shows
Data from published preclinical studies on KPV's anti-inflammatory, antimicrobial, and gut-healing effects.
Research context: KPV research is primarily preclinical — cell culture and animal models. Human clinical trials are extremely limited. The mechanistic data is strong, but translational evidence in humans is still emerging. Most studies come from university-affiliated immunology and gastroenterology labs.
Dosing Protocols
Community-reported dosing based on preclinical research and anecdotal use. These are not medical prescriptions.
- Dose: 200–500mcg per day
- Taken orally in capsule or sublingual form
- Best for gut inflammation, IBD, colitis symptoms
- Take on empty stomach for best absorption
- Often cycled: 4-8 weeks on, 2-4 weeks off
- May combine with BPC-157 for synergistic gut healing
- Dose: 200–500mcg per day SubQ
- For systemic anti-inflammatory effects
- Inject subcutaneously in abdomen or thigh
- Skin conditions, systemic inflammation
- Reconstitute with bacteriostatic water
- Store reconstituted peptide at 2-8°C
Why KPV is special: Most peptides are destroyed by stomach acid and digestive enzymes. KPV's size (just 3 amino acids — smaller than most dipeptides from protein digestion) allows it to be absorbed intact via the PepT1 transporter. This makes oral dosing genuinely viable, not just theoretical. Research Peptide — Not FDA Approved
Side Effects & Drug Interactions
Study Citations
Key Takeaways
- KPV inhibits NF-κB — the master inflammatory switch — in cell and animal studies
- Just 3 amino acids (Lys-Pro-Val) — shortest known therapeutic peptide
- Oral bioavailability confirmed via PepT1 transporter (extremely rare for peptides)
- Reduces colonic inflammation in DSS-induced colitis mouse models
- Antimicrobial against S. aureus and C. albicans
- No melanogenic side effects despite alpha-MSH origin
- Part of the KLOW blend (KPV + Larazotide + Oral BPC + Wolverine)
- No human clinical trials — all data is preclinical
- Optimal human dosing not established through controlled studies
- Long-term safety profile unknown in humans
- Whether oral bioavailability is sufficient for systemic (non-gut) effects
- Interaction profile with immunosuppressive drugs
- How it compares to BPC-157 for gut healing in controlled settings
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
🛒 Recommended Products
Supplies for peptide handling and gut health support.
Affiliate links help support HighPeptides at no extra cost to you.
Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. It is not medical advice. KPV is not FDA approved for any indication. It is classified as a research peptide. All data presented is from preclinical studies (cell culture and animal models) — no controlled human clinical trials have been published. Always consult a qualified healthcare provider before starting any new peptide or supplement protocol. HighPeptides does not sell KPV or endorse its use outside of legitimate research contexts.